Stewart, A., Paterson, D., Young, B., Lye, D., Davis, J., Schneider, K., . . . MEDICINE. (2021). Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Oxford University Press (OUP).
Chicago Style CitationStewart, AG, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused By AmpC β-Lactamase-Producing Enterobacter Spp, Citrobacter Freundii, Morganella Morganii, Providencia Spp, or Serratia Marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Oxford University Press (OUP), 2021.
MLA CitationStewart, AG, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused By AmpC β-Lactamase-Producing Enterobacter Spp, Citrobacter Freundii, Morganella Morganii, Providencia Spp, or Serratia Marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Oxford University Press (OUP), 2021.